Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Title of Study: A First-in-Human, Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-001 in Healthy Volunteers

NCT04994912 is registered in ClinicalTrials.gov with Elixiron Immunotherapeutics (Hong Kong) Ltd. as lead sponsor.

NCT NCT04994912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04994912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Title of Study: A First-in-Human, Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-001 in Healthy Volunteers
Lead sponsor
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2021
Completion date
February 18, 2025
Enrollment
35 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy